Regarding the efficacy of Tan IIA monotherapy on lung cancer, particularly NSCLC, Xie et al. (2015) discovered that Tan IIA inhibits VEGFR2 activity by binding to the kinase domain of VEGFR2 protein in NSCLC cell line A549 cells. This evidence concerns the gene KDR and non-small cell lung carcinoma.